Estados financieros detallados de Greenwich LifeSciences, Inc. (GLSI): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
Márgenes de los últimos 12 meses: margen bruto 0.0%, margen operativo 0.0%, margen neto 0.0%.
Al precio actual de $15.63, GLSI presenta beneficios negativos (P/E no significativo) y un ROE del -7.94%. La capitalización bursátil es de $229M.
Cuenta de Resultados (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Ingresos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Coste de Ventas | $3607 | $3607 | $3607 | $3609 | $3612 | $3612 | $3612 | $3612 | $1779 |
| Beneficio Bruto | -$3607 | -$3607 | -$3607 | -$3609 | -$3612 | -$3612 | -$3612 | -$3612 | -$1779 |
| I+D | $1.2M | $1.3M | $2.6M | $1.1M | $3.6M | $6.5M | $7.7M | $15.5M | $17.2M |
| Generales y Administrativos | $346812 | $419639 | $818887 | $806188 | $1.0M | $1.6M | $1.6M | $2.2M | $2.2M |
| Gastos Operativos | $1.6M | $1.7M | $3.4M | $1.9M | $4.6M | $8.0M | $9.3M | $17.6M | $19.4M |
| Beneficio Operativo | -$1.6M | -$1.7M | -$3.4M | -$1.9M | -$4.6M | -$8.0M | -$9.3M | -$17.6M | -$19.4M |
| EBITDA | -$1.6M | -$1.7M | -$3.4M | -$1.9M | -$4.6M | -$7.8M | -$8.9M | -$17.4M | -$19.4M |
| Gastos por Intereses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$1.6M | -$1.7M | -$3.4M | -$1.9M | -$4.6M | -$7.8M | -$8.9M | -$17.4M | -$19.4M |
| Impuestos | $3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$1.6M | -$1.7M | -$3.4M | -$1.9M | -$4.6M | -$7.8M | -$8.9M | -$17.4M | -$19.4M |
| BPA | $-0.13 | $-0.14 | $-0.29 | $-0.15 | $-0.35 | $-0.61 | $-0.69 | $-1.21 | $-1.43 |
| BPA Diluido | $-0.13 | $-0.14 | $-0.29 | $-0.15 | $-0.35 | $-0.61 | $-0.69 | $-1.21 | $-1.43 |
| Acciones en Circulación (Diluidas) | $11.7M | $12.0M | $11.7M | $12.7M | $12.9M | $12.9M | $12.8M | $13.0M | $13.5M |
Balance (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | $54 | $85102 | $6835 | $28.7M | $27.2M | $13.5M | $7.0M | $4.1M | $6.2M |
| Inversiones a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cuentas por Cobrar | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $54 | $85102 | $6835 | $28.7M | $27.2M | $13.5M | $7.0M | $4.1M | $6.2M |
| Inmovilizado Material | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fondo de Comercio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Intangibles | 0 | $23443 | $19836 | $16227 | $12615 | $9003 | $5391 | $1779 | 0 |
| Activos Totales | $27104 | $108545 | $26671 | $28.7M | $27.2M | $13.5M | $7.0M | $4.1M | $6.2M |
| Cuentas por Pagar | $161146 | $277556 | $730309 | $710971 | $220845 | $220845 | $35472 | $2.8M | $4.9M |
| Deuda a Corto | 0 | 0 | $635154 | $275154 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $557503 | $728599 | $1.4M | $1.0M | $385172 | $262905 | $294406 | $3.2M | $5.8M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $8.6M | $10.2M | $1.4M | $1.0M | $385172 | $262905 | $294406 | $3.2M | $5.8M |
| Reservas | -$22.1M | -$23.8M | -$27.2M | -$29.1M | -$33.6M | -$41.5M | -$50.4M | -$67.8M | -$87.1M |
| Patrimonio Neto | -$8.5M | -$10.1M | -$1.4M | $27.6M | $26.8M | $13.2M | $6.7M | $908626 | $353217 |
| Deuda Total | 0 | 0 | $635154 | $275154 | 0 | 0 | 0 | 0 | 0 |
| Deuda Neta | -$54 | -$85102 | $628319 | -$28.4M | -$27.2M | -$13.5M | -$7.0M | -$4.1M | -$6.2M |
| Capital Circulante | -$557449 | -$643497 | -$1.4M | $27.6M | $26.8M | $13.2M | $6.7M | $906847 | $353217 |
Flujo de Caja (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$1.6M | -$1.7M | -$3.4M | -$1.9M | -$4.6M | -$7.8M | -$8.9M | -$15.8M | -$19.4M |
| Amortizaciones | $3607 | $3607 | $3607 | $3609 | $3612 | $3612 | $3612 | $3612 | $1779 |
| Compensación en Acciones | 0 | 0 | $194943 | $677988 | $660582 | $1.7M | $2.4M | $7.3M | $6.8M |
| Cambio en Capital Circulante | $1.4M | $1.6M | $2.9M | $28403 | -$385166 | -$122267 | $31501 | $1.3M | $2.6M |
| Flujo de Caja Operativo | -$120847 | -$114952 | -$293267 | -$1.2M | -$4.3M | -$6.2M | -$6.5M | -$7.3M | -$9.9M |
| Inversiones (CapEx) | 0 | 0 | 0 | 0 | 0 | -$3 | 0 | $3 | $3 |
| Adquisiciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | -$90000 | 0 | 0 | 0 | 0 | -$7.5M | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$120847 | -$114952 | -$293267 | -$1.2M | -$4.3M | -$6.2M | -$6.5M | -$7.3M | -$9.9M |
Crecimiento y Márgenes (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Crecimiento Beneficio Neto (anual) | -7.4% | -102.7% | +45.6% | -145.4% | -71.2% | -13.6% | -95.8% | -11.2% | |
| Crecimiento BPA (anual) | -7.7% | -107.1% | +48.3% | -133.3% | -74.3% | -13.1% | -75.4% | -18.2% | |
| Cambio en Acciones (anual) | +1.9% | -1.9% | +8.2% | +1.9% | -0.2% | -0.5% | +1.3% | +4.0% | |
| Crecimiento FCF (anual) | +4.9% | -155.1% | -293.1% | -272.2% | -44.5% | -4.5% | -12.2% | -36.4% | |
| Tasa Impositiva Efectiva | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% | -0.0% |
Datos por Acción (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| FCF por Acción | $-0.01 | $-0.01 | $-0.02 | $-0.09 | $-0.33 | $-0.48 | $-0.50 | $-0.56 | $-0.73 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $11.7M | $12.0M | $11.7M | $12.7M | $12.9M | $12.9M | $12.8M | $13.0M | $13.5M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -793.76% |
| Rentabilidad sobre capital invertido | -701.55% |
| Rentabilidad sobre activos | -244.25% |
| Margen bruto | 0.00% |
| Margen operativo | 0.00% |
| Margen neto | 0.00% |
Salud financiera
| Deuda / Patrimonio | 0.00 |
| Ratio corriente | 1.54 |
Ratios Clave (10 años)
| Año | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| P/E | -38.46 | -35.71 | -17.24 | -243.13 | -69.51 | -24.92 | -15.25 | -9.28 | -14.69 |
| P/VC | -6.88 | -5.91 | -43.48 | 16.77 | 11.74 | 14.85 | 20.17 | 160.85 | 805.09 |
| P/V | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Margen Bruto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Operativo | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Margen Neto | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Empresas relacionadas: AGEN · ATOS · CGTX · HURA · IMMX · IRD · ONCY
Explorar sector: Healthcare · Biotechnology
Más secciones de GLSI: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones